

# The OIS as an IR Center of Excellence

Joel Rainwater, MD

Founder and CMO

Comprehensive Integrated Care




# Disclosure Statement of Financial Interest

CiC provides education, consultation and training  
for industry partners, including:  
SIRTEX, Philips, Abbott, Bard/BD, and Ra Medical

# COE: PAE

- 76 year old gentleman with BPH
- Severe LUTS with PSS of 34 (severe)
- Desires PAE for treatment



# Benign Prostatic Hypertrophy

- Most Common Male tumor
- Prevalance: Greater and 50% of men have histopathologic BPH by age 60
- Initial development in the 40s, increasing to 90% of men by age 80
- 50% of men have LUTS by age 60
- Affects QOL and sleep patterns



# Meta-Analysis of Prostatic Artery Embolization for Benign Prostatic Hyperplasia

Andre Uflacker, MD, Ziv J Haskal, MD, Tiago Bilhim, MD, James Patrie, MS, Timothy Huber, MD, and João Martins Pisco, MD

## ABSTRACT




**Purpose:** To perform meta-analysis of available data on prostatic artery embolization (PAE).

**Materials and Methods:** Meta-analysis was conducted on articles published between November 2009 and December 2015. Peer-reviewed studies with > 5 patients and standard deviations and/or individual-level data on one or more of the following outcomes were included: prostate volume (PV), peak flow rate (Qmax), postvoid residual (PVR), International Prostate Symptom Score (IPSS), quality of life (QOL) score, International Index of Erectile Function (IIEF) score, and prostate-specific antigen (PSA) level. A random-effects meta-analysis was performed on the outcomes at 1, 3, 6, and 12 months after PAE compared with baseline values, with a  $P < .05$  decision rule as the null hypothesis rejection criterion.

**Results:** Nineteen of 268 studies were included in data collection, with 6 included in the meta-analysis. At 12 months, PV decreased by  $31.31 \text{ cm}^3$  ( $P < .001$ ), PSA remained unchanged ( $P = .248$ ), PVR decreased by 85.54 mL ( $P < .001$ ), Qmax increased by 5.39 mL/s ( $P < .001$ ), IPSS improved by 20.39 points ( $P < .001$ ), QOL score improved by  $-2.49$  points ( $P < .001$ ), and IIEF was unchanged ( $P = 1.0$ ). There were a total of 218 adverse events (AEs) among 662 patients (32.93%), with 216 being Society of Interventional Radiology class A/B (99%). The most common complications were rectalgia/dysuria ( $n = 60$ ; 9.0%) and acute urinary retention ( $n = 52$ ; 7.8%). No class D/E complications were reported.

**Conclusions:** PAE provided improvement in Qmax, PVR, IPSS, and QOL endpoints at 12 months, with a low incidence of serious AEs (0.3%), although minor AEs were common (32.93%). There was no adverse effect on erectile function.










# How to “Get Out of Trouble” During Prostatic Artery Embolization

Ari J. Isaacson, MD

Rachel L. Piechowiak, DO,  
MS

Charles Nutting, DO, FSIR

Sandeep Bagla, MD



# Results

- Post PAE, 97% of patients reported a reduction of their IPSS score by at least 3 points
- 90% of patients dropped at least 1 symptom category, from severe to moderate or moderate to mild.
- Most patients also experienced an improvement in their Quality of Life score and a substantial decrease in prostate volume.
- 80% of men can stop one or all LUTS medications within 3 months.




# COE: Iliac Vein Reconstruction

- 37 yo woman
- Massive DVT during pregnancy 6 years prior
- Continued Pelvic Pain and Left leg swelling



























# COE: Thermal Ablation of Tumor



- Best For:
- Renal Malignancies in unfit surgical or nephron-sparing cases
- Liver Primary or Metastases as an adjunct to systemic therapy















Acc: #51800103  
Se: US #3001 - 1 Super  
Im: 7/13





Needle Unplugged

[ Jan 21 2015 ]  
TIB: 0.53  
[ F 068 ]  
[ 43383 ]  
TIC: 2.17  
TIS: 0.53  
MI: 1.05  
21fps  
98%  
**2D**  
H Mid  
5dB/DR60



C ●  
1024x768  
Zoom: 100 %  
Compression: 13:1 (lossless)  
W: 255 L: 128  
Z











# COE: Y90 & TACE


- 47 yo woman
- Colorectal CA s/p partial Colectomy
- Two large Right hepatic metastatic lesions on surveillance post FOLFOX chemotherapy













# COE: UFE



## *U.S. STATISTICS*


Most common pelvic mass in women



- prevalence: 20-40% (= millions)
- 75%: asymptomatic
- 25%: bleeding, pain, bulk symptoms
- 600,000 Hysterectomies annually
- approximately 1/3 for fibroids
- cost: \$4 Billion















# Outpatient Interventional Procedures:

- -Are appropriate and Safe
- -Effective
- -Durable
- -Cost Efficient
- -Convenient
- -Result in High Patient Satisfaction

# Thank You!

[jrainwater@ciccenters.com](mailto:jrainwater@ciccenters.com)

Joel Rainwater, MD  
Founder and CMO

Comprehensive Integrated Care

